ClinicalTrials.gg

Program

NH102

A development code.

Its studies are mostly in Depression · Depressive Disorder, Major, led by Jiangsu Nhwa Pharmaceutical.

Furthest: phase 2, since Feb 16, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu Nhwa Pharmaceutical30 open or runningphase 2since Feb 16, 2025Aug 19, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 19, 2021First study: phase 1 study in DepressionFirst studyNCT05015192 · 55 enrolled · China
  2. Feb 16, 2025Phase 2 study in Depressive Disorder, MajorNCT06842992 · 243 enrolled · China
  3. Dec 10, 2025Phase 1 study in DepressionNCT07324408 · 40 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07324408Depression · China1CompletedApr 10, 202340
NCT06842992Depressive Disorder, Major · China2CompletedJul 30, 2025243
NCT05015192Depression · China1CompletedJan 11, 202255

How it is read

Names in the registry

  • “NH102”, 5 entries

Codes read as this program: NH102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
NH102 (Jiangsu Nhwa Pharmaceutical): development program | ClinicalTrials.gg